InvestSMART

Emyria Limited (ASX:EMD)

ALERT: Price-sensitive ASX Announcement for EMD
Current share price for EMD : $0.045 -0.003 (-6.25%)+
Announcement
Release
5 May 2026 8:34AM
Price at Release
$0.048
Full Release
download
Summary
Emyria Limited's March Quarter Investor Video Presentation, held in May 2026, highlighted key achievements including a $1.2 million revenue growth for the quarter and the launch of a Global Partnership Program targeting international drug sponsors. The company reported durable clinical outcomes in their PTSD program, with 76% of patients achieving significant improvement and 67% remaining in remission 12 months post-treatment. Emyria is expanding its clinical presence with the first Victorian clinic on track for commencement in the second quarter of FY26, and a new clinic announced in New South Wales. The company is focusing on supporting global psychedelic-assisted therapy programs through its established clinical network. Future catalysts for Emyria include expanding clinic capacity, introducing new indications to broaden market potential, and adding new drug partners to their Global Partnership Program. The company also highlighted its robust real-world data collection and innovative treatment approaches for mental health conditions.
Key Points
  • Emyria achieved $1.2 million revenue growth in March Quarter.
  • Global Partnership Program launched for international drug sponsors.
  • 76% of PTSD program participants showed significant improvement.
  • 67% of PTSD patients remained in remission 12 months post-treatment.
  • Expansion with the first Victorian clinic and a new clinic in NSW.
  • Focus on supporting global psychedelic-assisted therapy programs.
  • Plans to expand clinic capacity and introduce new indications.
  • Real-world data collection enhances therapy and drug development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.